Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 58Neoplasm Metastasis 3Prostate Adenocarcinoma 2Neoplasms 2Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel 1Metabolic Syndrome 1Hypogonadism 1Fatty Liver 1Castration-resistant Prostate Cancer Patients with Oligometastases 1

Interventions

Triptorelin Pamoate 1Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel × Triptorelin Pamoate × Genitourinary × Clear all
NCT04869371 2022-12-29

Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
75 enrolled
Genitourinary

Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel

Data powered by HemOnc (CC BY 4.0) Colophon âš¡